What to Expect in Your First 3 Months on a GLP-1

The first three months on a GLP-1 are the most impactful of your entire treatment. It's when side effects are most common, when dose titration is still happening, and when you're forming the habits and expectations that determine whether therapy works for you long-term. This guide walks through it week by week.

Qualitative timeline of what most patients experience on injectable semaglutide or tirzepatide

The timeline above is a common example of what to expect during the early phase of titration, but your experience may vary. It does not project specific weight-loss outcomes for any individual.

Dose typically steps up every 4 weeks, but your timeline may differ based on your provider's recommendations and how well you tolerate the medication. Some people need a slower titration and that is completely normal. It usually takes at least 4–6 months to reach a steady maintenance dose of semaglutide or tirzepatide.

Before your first injection

Whether you start with semaglutide or tirzepatide, the preparation is similar. Your provider will usually recommend:

• Complete baseline labs if your program includes them — A1c, lipid panel, liver/kidney function
• Stock your pantry with gentle foods — bone broth, plain yogurt, crackers, bananas, ginger tea. You'll be grateful for these if nausea hits
• Have an anti-nausea plan — try OTC options like ginger chews or Dramamine, or ask your prescriber about an Rx medication like ondansetron
• Order fiber and a stool softener — constipation is almost certain at some point; prepare before you need it
• Clear your calendar for the first few days — most people are fine, but a small minority are hit hard by first-dose nausea. Don't schedule anything critical
• Pick your injection day strategically — most patients inject on a Sunday evening or Monday morning so peak GI effects (36–72 hours post-dose) land on workdays when they're home-base rather than traveling

Your medication will usually arrive as a pen (for brand-name Wegovy® or Zepbound®) or a vial with syringes (for compounded versions). Zepbound® is also available in vial form. Wegovy® has an oral tablet option. How to inject semaglutide walks through the actual injection technique.

Weeks 1–4: the starter dose

The starter dose is intentionally low — 0.25 mg for semaglutide, 2.5 mg for tirzepatide. The point is not to produce weight loss yet. The point is to let your body adapt to having GLP-1 receptors activated to minimize GI side effects.

Day 1–3 after your first dose

Most people feel something subtle — mild nausea, slightly decreased appetite, maybe a little bit of fatigue. A small minority feel nothing. An even smaller minority feel quite unwell — intense nausea, vomiting, or significant fatigue. If you're in that last group, message your provider; dose adjustments and anti-nausea medication help.

Typical day-1 patterns:

• Nausea commonly starts 24–48 hours after first dose
• Fatigue may show up in the afternoon or evening of day 1–2
• Slight appetite reduction is usually noticeable by day 3

Days 4–7

Nausea can come and go and may build over the first week or two as your body adjusts to the medication. Appetite reduction becomes more obvious. You may find you're not thinking about food as constantly — this is often the first really noticeable change.

Weeks 2–4

Your body is adjusting to the starter dose. Appetite is consistently reduced; meals feel smaller; cravings — especially for sugar and ultra-processed food — often diminish significantly. Any weight change in the first month is highly individual and depends on starting weight, adherence, and lifestyle.

Common surprises in weeks 2–4:

• Alcohol tolerance drops noticeably. Many patients find they lose interest in drinking entirely
• Food preferences shift. High-fat or high-sugar foods may suddenly taste "too much" or feel heavy
• Hydration becomes critical. You're eating less, so you're getting less water from food. Aim for 80–100 oz/day from fluids
• Protein is easy to undereat. With appetite suppressed, most people gravitate toward carbs because they're easier to eat. Actively choose protein-forward meals

Week 5: first dose increase

Around week 5, you'll step up to the next dose (0.5 mg semaglutide or 5 mg tirzepatide). This is the most common re-entry point for side effects — another wave of mild to moderate nausea, often lasting a week or two, is typical.

Here's a surprise most people don't anticipate: adjusting to dose increases often gets easier, not harder, from here. Your body has been working on GLP-1 for a month — each subsequent step is a smaller relative change.

Weeks 6–8: the sweet spot

This is usually when people start to notice real changes in how they feel and possibly the number on the scale. Any weight change to date is highly individual.

What typically happens in this window:

• Calorie intake about 20–40% lower than pre-medication
• Snacking becomes rare, then feels weird
• Some people report decreased "food noise" — the constant background thinking about food fades
• Exercise tolerance may improve as weight comes off
• Clothes feel different (usually before the scale reflects it fully)

Psychological caution in weeks 6–8: a lot of patients start eating too little. If appetite is strongly suppressed, it's easy to drop to 1,000–1,200 calories a day without noticing. This is counterproductive — you lose muscle, metabolism adapts downward, and you feel bad. Use our TDEE calculator to find your maintenance and cut targets; don't go below 1,200 (women) or 1,500 (men) without your provider's guidance.

Week 9: second dose increase

Third dose level now (1.0 mg semaglutide or 7.5 mg tirzepatide). Similar pattern to week 5 — brief side effect wave, then back to normal. Your provider will assess whether to continue increasing or hold at this dose based on your progress.

Not everyone needs to reach the maximum dose. Some patients do very well at mid-levels and continue there indefinitely. Maximum dose is 7.2 mg semaglutide or 15 mg tirzepatide.

Weeks 10–12: the new normal

By the end of three months, most patients who respond well have:

• Established a stable routine around physical activity and meal patterns
• Adapted their grocery shopping, meal prep, and eating-out decisions
• Reduced side effects

From there, titration may continue every 4 weeks until you reach the dose that's right for you.

What FDA-approved trials of brand-name products reported (for context only — not a prediction for compounded medications):

• STEP UP (FDA-approved Wegovy®, semaglutide): ~10% average body weight loss at 20 weeks; ~19% at 72 weeks with 7.2 mg dose
• SURMOUNT-1 (FDA-approved Zepbound®, tirzepatide): ~13% average body weight loss at 20 weeks; ~20% at 72 weeks with 15 mg dose

Those results were observed with the FDA-approved products studied in those trials. They have not been clinically established for compounded medications. Individual outcomes vary by starting weight, dose, adherence, and lifestyle; outcomes are not guaranteed.

The most common mistakes in the first 3 months

1. Quitting during titration side effects. The first two weeks of each dose increase are the hardest, but they fade reliably as your body adjusts. You learn to make small changes in what you eat and drink to help manage side effects.

2. Not eating enough protein. You lose weight regardless, but it's the wrong kind (lean mass). Protein first, even when you don't feel hungry for high-protein foods.

3. Not drinking enough water. Mild dehydration amplifies every GLP-1 side effect. Most patients need 20–30% more water than they used to because they're getting less from food.

4. Skipping meals. A skipped meal doesn't speed up weight loss — it leaves you dehydrated, micronutrient-depleted, and more likely to bring on nausea.

5. Obsessing over the weekly scale. Weight loss on GLP-1 isn't linear. You'll have weeks where you lose 2 lbs and weeks where you lose nothing — sometimes weeks where you gain temporarily due to water retention. The trendline over a month is what matters.

6. Not building muscle. Any resistance training — even bodyweight twice a week — dramatically improves body composition outcomes. See our nutrition guide: best foods to eat on semaglutide.

7. Forgetting to tell your provider things. If something is weird — persistent pain, significant fatigue that doesn't resolve, mood changes, hair loss starting — tell them. These are fixable with adjustments or supplementation.

What success can look like at 3 months

Most patients who respond well to GLP-1 therapy notice the following changes by the end of month 3 (qualitative — not a guaranteed outcome):

• Smaller meals feel normal — no longer fighting appetite most of the time
• Clearer pattern of what foods work — you'll know which foods trigger side effects and which don't
• More predictable energy and routine — as your body adjusts to the medication

A subset of patients are "non-responders" — they tolerate the medication fine but don't see meaningful weight change. Your provider will assess whether to change medication, adjust dose, or explore other factors (thyroid function, sleep, medication interactions) if you're in this group.

References

The titration schedules and trial figures referenced above come from the FDA-approved prescribing information for the branded products and their pivotal trials. All efficacy data reflect the FDA-approved branded products at the doses studied and have not been established for compounded preparations.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
3. U.S. Food and Drug Administration. WEGOVY® (semaglutide) prescribing information. 2026.
4. U.S. Food and Drug Administration. ZEPBOUND® (tirzepatide) prescribing information. 2026.
5. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory. Am J Clin Nutr. 2025;122(1):344–367.
6. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated With GLP-1 Receptor Agonists. J Clin Med. 2023;12(1):145.
7. Kushner RF, Almandoz JP, Rubino DM. Managing Adverse Effects of Incretin-Based Medications for Obesity. JAMA. 2025;334(9):822–823.
8. Wharton S, Freitas P, Hjelmesæth J, et al. [Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25\)00226-8/fulltext). Lancet Diabetes Endocrinol. 2025;13(11):949–963.
9. Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024;11:100121.

Bottom line: The first month is mostly about making small adjustments to help manage GI side effects. Month 2 is when benefits start to crystallize for some people. Month 3 sets up your long-term pattern. The two things that matter most during this window are lifestyle adjustments (working out, protein intake, hydration, etc.) and a provider who answers your messages.